A Chance For 20% Gains With Aastrom Biosciences (ASTM)
Contrarian Profits (November 28th, 2008) Writes:
Laura Cadden says Aastrom Biosciences, Inc. (NASDAQ:ASTM) is one of the hottest biotech stocks priced under $5. The company hopes to use its proprietary Tissue Repair Cell (TRC) technology to revolutionise treatment for heart disease. And it is making good progress through the trial phases. Laura says Aastrom is poised to make 20% gains in six months
This from Today’s Financial News:
Investors expect President-Elect Obama to make good on his campaign promise to lift restrictions on federally funding human embryonic stem cell research. House Speaker Nancy Pelosi has vowed to introduce legislation for a regulatory framework necessary to enable expanded stem cell research.
Biotechnology experts consider both the regulatory framework (to underpin clinical trials) and the additional funding to be crucial to the future of the American bio-pharma industry. In fact, it could ring in a new era for American stem cell
...Aastrom Biosciences Inc.;, alcoholism;, Biotechnology, Biotechnology experts;, Cardiac Repair Cells;, cardiomyopathy;, cent;, congestive heart failure;, contrarian profits, CRCs;, Dilated cardiomyopathy;, Germany, heart attacks;, Heart Disease, hypertension, Internet rumor;, Laura Cadden, mainstream media, Market Commentary, mixed-cell products;, Nancy Pelosi, Nasdaq 100, treatment for heart disease;, U.S. Food and Drug Administration, United States, USD


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)



